# reload+after+2024-01-22 16:45:23.414019
address1§325 East Middlefield Road
city§Mountain View
state§CA
zip§94043
country§United States
phone§650 965 7873
website§https://igmbio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's product candidate, including imvotamab (IGM-2323), an IgM-based CD20 x CD3 bispecific antibody T cell engager that is in Phase 2 clinical trials for the treatment of B cell non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1a/1b clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody that is in Phase 1 clinical trials for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
fullTimeEmployees§290
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Fred M. Schwarzer J.D.', 'age': 70, 'title': 'CEO, President & Director', 'yearBorn': 1953, 'fiscalYear': 2022, 'totalPay': 977658, 'exercisedValue': 0, 'unexercisedValue': 4365618}, {'maxAge': 1, 'name': 'Dr. Bruce A. Keyt', 'age': 70, 'title': 'Chief Scientific Officer', 'yearBorn': 1953, 'fiscalYear': 2022, 'totalPay': 692954, 'exercisedValue': 0, 'unexercisedValue': 3441786}, {'maxAge': 1, 'name': 'Dr. Chris H. Takimoto FACP, M.D., Ph.D.', 'age': 64, 'title': 'Chief Medical Officer', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 684953, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Misbah  Tahir', 'age': 48, 'title': 'Chief Financial Officer', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 957600, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. TS  Harigopal', 'title': 'Senior Vice President of Group Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Steven  Weber', 'age': 47, 'title': 'Senior VP, Corporate Controller & Principal Accounting Officer', 'yearBorn': 1976, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Paul C. Graffagnino', 'title': 'Vice President of Legal Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Suzette  Tauber', 'age': 59, 'title': 'Chief Human Resources Officer', 'yearBorn': 1964, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Angus M. Sinclair Ph.D.', 'title': 'Senior Vice President of Immuno-Oncology', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Lisa L. Decker Ph.D.', 'age': 53, 'title': 'Chief Business Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 528182, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§9
compensationRisk§9
shareHolderRightsRisk§10
overallRisk§10
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.235
priceToSalesTrailing12Months§318.94345
currency§USD
dateShortInterest§1702598400
forwardEps§-3.84
exchange§NMS
quoteType§EQUITY
shortName§IGM Biosciences, Inc.
longName§IGM Biosciences, Inc.
firstTradeDateEpochUtc§1568813400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§ec470288-8a03-31b9-966a-7fa24c6a00fa
gmtOffSetMilliseconds§-18000000
targetHighPrice§48.0
targetLowPrice§7.0
targetMeanPrice§18.7
targetMedianPrice§16.0
recommendationMean§2.1
recommendationKey§buy
numberOfAnalystOpinions§10
quickRatio§9.007
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
